NovoBliss Research provides comprehensive research and development services across Pharmaceuticals, Nutraceuticals, Ayurvedic, and Herbal products. Our offerings include:

• Preclinical and clinical trial management
• Regulatory affairs and compliance support
• Formulation development and stability studies
• Analytical testing and bioavailability assessments
• Safety and efficacy evaluations

NovoBliss Research adheres to global regulatory standards, including Good Clinical Practice (GCP), Good Publication Policy (GPP) and Good Laboratory Practice (GLP). We maintain rigorous documentation, implement robust Quality Assurance (QA) and Quality Control (QC) processes, and stay updated with the latest regulatory requirements to ensure compliance throughout the research process.

We employ a patient-centric approach, utilizing digital platforms, healthcare provider networks, and community outreach to identify and recruit suitable participants. Our dedicated study coordinators provide continuous support to participants, ensuring high retention rates and adherence to study protocols.

Yes. We perform dermatological safety evaluations such as PIPT (Primary Irritation Patch Test) and HRIPT (Human Repeated Insult Patch Test) to ensure products are safe, well-tolerated, and regulatory-compliant.

Yes. Every project is tailored to meet client-specific objectives, whether it’s a unique formulation, targeted clinical study, or specialized analytical evaluation.

• Multidisciplinary expertise across Pharmaceuticals, Nutraceuticals, Ayurvedic, and Herbal products
• State-of-the-art laboratory and analytical instrumentation
• Strong emphasis on QA and QC for high-quality, regulatory-compliant data
• End-to-end support from formulation to clinical validation and regulatory advising.

Yes, we perform clinical safety, efficacy, and consumer in-use studies, including non-acnegenic, sensory, and scaled efficacy evaluations, in collaboration with dermatology, ophthalmology, and other domain experts.

Yes, NovoBliss Research ensures that all testing and clinical studies adhere to the regulatory standards of major health authorities, including the US FDA, EMA, CDSCO (India), Health Canada (NHP), and Australia’s TGA.

By providing comprehensive testing services that align with international regulatory requirements, NovoBliss Research supports clients in obtaining necessary approvals and ensuring product safety and efficacy across diverse markets.

Yes, NovoBliss Research provides comprehensive support for CTRI registration, including guidance on documentation, ethical approvals, and regulatory submissions, ensuring compliance with Indian clinical trial regulations.

Yes, as per the Drugs Controller General of India (DCGI), registration of all clinical trials in India is mandatory through the Clinical Trials Registry – India (CTRI) before enrolling participants.

Yes, consumer in-use studies, surveys, and efficacy assessments can be conducted online or remotely for scalable, geographically unrestricted insights.

Yes, our data and testing protocols are designed to meet the expectations of agencies such as US FDA, EMA, CDSCO, Health Canada (NHP), and Australia TGA.

Yes, our team collaborates with clients to design study protocols aligned with scientific objectives, regulatory requirements, and industry best practices.

All client data is handled under strict confidentiality agreements and secure data management systems to protect proprietary information.